US6770283B1
(en)
*
|
1990-12-13 |
2004-08-03 |
Bioption Ab |
DNA expression systems based on alphaviruses
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
DE69435224D1
(de)
*
|
1993-09-15 |
2009-09-10 |
Novartis Vaccines & Diagnostic |
Rekombinante Alphavirus-Vektoren
|
SE9401091D0
(sv)
*
|
1994-03-31 |
1994-03-31 |
Bioption Ab |
Alphavirus cDNA vectors
|
SE9401709D0
(sv)
*
|
1994-05-18 |
1994-05-18 |
Mathilda Sjoeberg |
Improved alphavirus vectors for expression of heterologous DNA
|
US5505947A
(en)
*
|
1994-05-27 |
1996-04-09 |
The University Of North Carolina At Chapel Hill |
Attenuating mutations in Venezuelan Equine Encephalitis virus
|
DE19512142A1
(de)
*
|
1995-03-31 |
1996-10-02 |
Immuno Ag |
Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
US5639650A
(en)
*
|
1995-05-23 |
1997-06-17 |
The University Of North Carolina At Chapel Hill |
cDNA clone for South African Arbovirus No. 86
|
US6451592B1
(en)
*
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
US6458560B1
(en)
|
1996-04-05 |
2002-10-01 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
US5939262A
(en)
|
1996-07-03 |
1999-08-17 |
Ambion, Inc. |
Ribonuclease resistant RNA preparation and utilization
|
US5677124A
(en)
*
|
1996-07-03 |
1997-10-14 |
Ambion, Inc. |
Ribonuclease resistant viral RNA standards
|
AU4737597A
(en)
*
|
1996-09-25 |
1998-04-17 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
|
EP0932693A1
(de)
*
|
1996-10-10 |
1999-08-04 |
Henrik Garoff |
Alphavirus-retrovirus vektoren
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US5811407A
(en)
|
1997-02-19 |
1998-09-22 |
The University Of North Carolina At Chapel Hill |
System for the in vivo delivery and expression of heterologous genes in the bone marrow
|
US6432699B1
(en)
*
|
1997-03-28 |
2002-08-13 |
New York University |
Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
|
EP1025212B1
(de)
|
1997-10-14 |
2007-09-26 |
Darwin Molecular Corporation |
Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
|
CA2308606A1
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
US20030180257A1
(en)
|
1997-11-14 |
2003-09-25 |
Mark Parrington |
Alphavirus vectors for paramyxovirus vaccines
|
PT1047784E
(pt)
|
1998-01-14 |
2009-12-21 |
Novartis Vaccines & Diagnostic |
Antigénios de neisseria meningitidis
|
US6844188B1
(en)
|
1998-04-08 |
2005-01-18 |
University Of North Carolina At Chapel Hill |
Methods and modified cells for the treatment of cancer
|
DE69942006D1
(de)
|
1998-04-08 |
2010-03-25 |
Univ North Carolina |
Krebsimpfstoff enthaltend alphavirusrepliconpartikeln
|
EP2261343A3
(de)
|
1998-05-01 |
2012-01-18 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene und Zusammensetzungen gegen Neisseria meningitidis
|
CA2327353C
(en)
*
|
1998-05-08 |
2010-09-21 |
Akzo Nobel Nv |
Structural proteins of fish pancreatic disease virus and uses thereof
|
JP2002527066A
(ja)
|
1998-10-15 |
2002-08-27 |
カイロン コーポレイション |
転移性乳癌および結腸癌調節遺伝子
|
ES2317711T3
(es)
*
|
1998-11-30 |
2009-04-16 |
Cytos Biotechnology Ag |
Presentacion molecular de alergenos, metodos de preparacion y uso.
|
PT1141331E
(pt)
|
1998-12-16 |
2008-12-22 |
Novartis Vaccines & Diagnostic |
Quinase dependente de ciclina humana (hpnqalre)
|
US8647864B2
(en)
|
1999-04-14 |
2014-02-11 |
Novartis Ag |
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
|
DK1175497T3
(da)
*
|
1999-04-14 |
2010-05-31 |
Novartis Vaccines & Diagnostic |
Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
|
PT1228217E
(pt)
|
1999-04-30 |
2013-01-28 |
Novartis Vaccines & Diagnostic |
Antígenos de neisseria conservados
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
US6297013B1
(en)
|
1999-06-24 |
2001-10-02 |
Dnab Diagnostics Inc. |
Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
CA2721011A1
(en)
|
1999-10-22 |
2001-05-03 |
Aventis Pasteur Limited |
Modified gp100 and uses thereof
|
EP1226263A1
(de)
*
|
1999-10-26 |
2002-07-31 |
International Aids Vaccine Initiative |
Invasive bakterielle vektoren für die expression von alphavirus replikons
|
ES2564463T3
(es)
|
1999-10-29 |
2016-03-22 |
Glaxosmithkline Biologicals S.A. |
Péptidos antigénicos de Neisseriales
|
EP1232264B1
(de)
|
1999-11-18 |
2009-10-21 |
Novartis Vaccines and Diagnostics, Inc. |
Menschliches fgf-21 gen und genexpressionsprodukte
|
BRPI0107679B8
(pt)
|
2000-01-17 |
2021-05-25 |
Chiron Spa |
composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
|
AU2001249125A1
(en)
|
2000-03-08 |
2001-09-17 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
WO2001085208A2
(en)
|
2000-05-05 |
2001-11-15 |
Cytos Biotechnology Ag |
Molecular antigen arrays and vaccines
|
ATE346925T1
(de)
|
2000-05-10 |
2006-12-15 |
Sanofi Pasteur Ltd |
Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
|
ES2312447T3
(es)
|
2000-05-31 |
2009-03-01 |
Novartis Vaccines And Diagnostics, Inc. |
Procedimiento para la purificacion de particulas de replicon alfavirus.
|
US6783939B2
(en)
|
2000-07-07 |
2004-08-31 |
Alphavax, Inc. |
Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
|
AU2001290642A1
(en)
|
2000-09-07 |
2002-03-22 |
University Of North Carolina At Chapel Hill |
Vectors derived from south african arbovirus no. 86
|
IL154853A0
(en)
|
2000-10-27 |
2003-10-31 |
Chiron Spa |
Nucleic acids and proteins from streptococcus groups a & b
|
AU2715302A
(en)
|
2000-12-08 |
2002-06-18 |
Invitrogen Corp |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US7264810B2
(en)
|
2001-01-19 |
2007-09-04 |
Cytos Biotechnology Ag |
Molecular antigen array
|
US7094409B2
(en)
*
|
2001-01-19 |
2006-08-22 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of allergic eosinophilic diseases
|
US7128911B2
(en)
*
|
2001-01-19 |
2006-10-31 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of bone disease
|
AU2002258631B2
(en)
*
|
2001-03-27 |
2007-05-17 |
New York University |
Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
AU2002305151A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
EP2842964A1
(de)
|
2001-06-05 |
2015-03-04 |
Curevac GmbH |
Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
|
DE60233061D1
(de)
|
2001-09-06 |
2009-09-03 |
Alphavax Inc |
Alphavirus replikon-vektorsysteme
|
MXPA04002644A
(es)
|
2001-10-05 |
2004-07-08 |
Cytos Biotechnology Ag |
Conjugados que portan un peptido de angiotensina y usos de los mismos.
|
US7115266B2
(en)
*
|
2001-10-05 |
2006-10-03 |
Cytos Biotechnology Ag |
Angiotensin peptide-carrier conjugates and uses thereof
|
NZ562929A
(en)
|
2001-12-12 |
2009-07-31 |
Novartis Vaccines & Diagnostic |
Immunisation against chlamydia trachomatis
|
US7877273B2
(en)
*
|
2002-01-08 |
2011-01-25 |
Fredric David Abramson |
System and method for evaluating and providing nutrigenomic data, information and advice
|
US20030219459A1
(en)
*
|
2002-01-18 |
2003-11-27 |
Cytos Biotechnology Ag |
Prion protein carrier-conjugates
|
KR100981471B1
(ko)
|
2002-03-15 |
2010-09-10 |
더 큐레이터스 오브 더 유니버시티 오브 미주리 |
효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의p4 변형 단백질
|
DE60315628T2
(de)
|
2002-04-09 |
2008-06-05 |
Sanofi Pasteur Ltd., Toronto |
Modifizierte cea nucleinsäure und expressionsvektoren
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
BR0311995A
(pt)
*
|
2002-06-20 |
2005-04-05 |
Cytos Biotechnology Ag |
Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
|
CN102061288A
(zh)
|
2002-07-17 |
2011-05-18 |
希托斯生物技术股份公司 |
使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
|
KR20120041739A
(ko)
*
|
2002-07-18 |
2012-05-02 |
사이토스 바이오테크놀로지 아게 |
합텐-캐리어 컨쥬게이트 및 그의 용도
|
PT1524994E
(pt)
|
2002-07-19 |
2011-08-01 |
Cytos Biotechnology Ag |
Composições de vacina contendo fileiras de antigénio amilóide beta 1-6
|
DE60332377D1
(de)
|
2002-10-21 |
2010-06-10 |
Eisai Inc |
Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
|
EP2279746B1
(de)
|
2002-11-15 |
2013-10-02 |
Novartis Vaccines and Diagnostics S.r.l. |
Oberflächenproteine in neisseria meningitidis
|
JP4991108B2
(ja)
|
2002-12-13 |
2012-08-01 |
アルファバックス,インコーポレイティド |
多抗原性アルファウイルス・レプリコン粒子及び方法
|
AU2003297041B2
(en)
|
2002-12-13 |
2009-02-26 |
Alphavax, Inc. |
Alphavirus particles and methods for preparation
|
JP2006517790A
(ja)
*
|
2003-01-09 |
2006-08-03 |
インヴィトロジェン コーポレーション |
ポリペプチド−核酸複合体の細胞の送達および活性化
|
AU2004223477B2
(en)
|
2003-03-20 |
2009-03-26 |
Alphavax, Inc. |
Improved alphavirus replicons and helper constructs
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
WO2004102198A2
(en)
*
|
2003-05-15 |
2004-11-25 |
Cytos Biotechnology Ag |
Selection of b cells with specificity of interest: method of preparation and use
|
DK1651666T3
(da)
*
|
2003-07-11 |
2009-08-31 |
Alphavax Inc |
Alfavirus-baserede cytomegalovirusvacciner
|
US7910093B2
(en)
|
2003-08-19 |
2011-03-22 |
New York University |
Method for detecting cancer cells and monitoring cancer therapy
|
ATE506444T1
(de)
*
|
2003-10-08 |
2011-05-15 |
Sanofi Pasteur Ltd |
Modifizierter cea/b7-vektor
|
KR20060128924A
(ko)
*
|
2004-01-20 |
2006-12-14 |
사이토스 바이오테크놀로지 아게 |
그레린-담체 접합체
|
EP1736541B1
(de)
|
2004-03-29 |
2013-01-23 |
Galpharma Co., Ltd. |
Neues modifizierte galectin-9 protein und dessen verwendung
|
AU2005245956B2
(en)
*
|
2004-05-18 |
2011-05-19 |
Alphavax, Inc. |
TC-83-derived alphavirus vectors, particles and methods
|
ES2292271B1
(es)
*
|
2004-05-20 |
2009-02-16 |
Proyecto De Biomedicina Cima, S.L. |
Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
|
RU2006146605A
(ru)
*
|
2004-06-02 |
2008-07-20 |
Цитос Биотехнологи Аг (Ch) |
Медицинские применения конъюгатов-носителей tnf-пептидов из организма кроме человека
|
WO2005122675A2
(en)
*
|
2004-06-21 |
2005-12-29 |
Quattromed As |
Optimized recognition site of the alphavirus non-structural protease for tag removal and specific processing of recombinant proetins
|
AU2005327198B2
(en)
|
2004-07-09 |
2011-03-31 |
University Of North Carolina At Chapel Hill |
Viral adjuvants
|
US7998733B2
(en)
|
2004-10-05 |
2011-08-16 |
Merial Limited |
Chimeric vectors
|
AU2006302794B2
(en)
|
2005-02-15 |
2011-08-04 |
Children's Hospital, Inc. |
New live virus vaccines
|
EA037929B1
(ru)
|
2005-03-23 |
2021-06-08 |
Генмаб А/С |
Антитела к cd38 человека и их применение
|
US7303898B2
(en)
*
|
2005-03-29 |
2007-12-04 |
New York University |
Defective sindbis viral vectors
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
CA2663295C
(en)
|
2006-09-12 |
2020-03-10 |
Alphavax, Inc. |
Alphavirus replicon particles matched to protein antigens as immunological adjuvants
|
EP2066346B1
(de)
|
2006-09-12 |
2019-07-03 |
AlphaVax, Inc. |
Für il-12 kodierende alphavirusreplikationspartikel als immunologische hilfsstoffe
|
ES2673823T3
(es)
|
2006-11-03 |
2018-06-25 |
Alphavax, Inc. |
Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
|
EP2139447A2
(de)
|
2007-03-20 |
2010-01-06 |
Harold Brem |
Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
|
AU2008266807B2
(en)
|
2007-06-21 |
2012-08-16 |
Alphavax, Inc. |
Promoterless cassettes for expression of alphavirus structural proteins
|
PT2222697E
(pt)
|
2007-11-01 |
2013-02-15 |
Perseid Therapeutics Llc |
Polipeptídeos imunossupressores e ácidos nucleicos
|
ES2525707T3
(es)
|
2008-12-01 |
2014-12-29 |
Alphavax, Inc. |
Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
|
AU2010234362B2
(en)
|
2009-04-08 |
2015-11-26 |
Alphavax, Inc. |
Alphavirus replicon particles expressing TRP2
|
WO2011038063A1
(en)
|
2009-09-28 |
2011-03-31 |
The Trustees Of The University Of Pennsylvania |
Method of diagnosing and treating interstitial cystitis
|
EE05711B1
(et)
|
2009-10-07 |
2014-04-15 |
Tartu Ülikool |
Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
|
WO2011064437A2
(es)
|
2009-11-26 |
2011-06-03 |
Proyecto De Biomedicina Cima, S.L. |
Vectores virales y procedimientos útiles en la preparación de gdnf
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
EP2698635A3
(de)
|
2010-12-01 |
2014-05-28 |
The University Of North Carolina At Chapel Hill |
Verfahren und Zusammensetzungen zum Targeting auf Stellen neovaskulären Wachstums
|
WO2012101509A2
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi Pasteur Sa |
Immunological compositions against hiv
|
HUE037408T2
(hu)
|
2011-06-10 |
2018-08-28 |
Univ Oregon Health & Science |
CMV glikoproteinek és rekombináns vektorok
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
US20190282679A1
(en)
*
|
2016-04-18 |
2019-09-19 |
Rima McLeod |
Toxoplasma gondii vaccines and their use
|
CA3054323A1
(en)
*
|
2017-02-27 |
2018-08-30 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
EP4010350A4
(de)
|
2019-08-09 |
2023-11-22 |
Nutcracker Therapeutics, Inc. |
Verfahren und vorrichtungen zur herstellung für die entfernung von material aus einer therapeutischen zusammensetzung
|